MalariaNCT05736679
EaveTubes for Vector Control
A study testing In2Care EaveTube in people with Malaria, run by University of Notre Dame at 1 site in Côte d’Ivoire.
Trial summary
The goal of this clinical trial is to test whether In2Care EaveTubes (ETs) as a stand-alone tool can reduce malaria in an area where transmission is driven by insecticide-resistant Anopheles gambiae. Read more about this study
- Who is it for?
- Ages 6 months to 10 yearsHealthy volunteers can take part
- Conditions the study is for
- Malaria
- What is being tested?
- In2Care EaveTube
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,870 participants
- Where
- 1 siteCôte d’Ivoire
- Study dates
- 23 Mar 2023to Dec 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 months to 10 years
- All sexes
- Healthy volunteers accepted
- Child
Village Level Inclusion Criteria:
- ≥ 80% of Households (HHs) must be suitable for EaveTube(ET) installation.
- ≥70% of HHs willing to have ETs installed.
- No participation in the previous Screening + ETs cluster randomized control trial (cRCT).
- Received standard pyrethroid-only long lasting insecticide nets(LLINs) (Permanet 2.0).
- 100-300 HHs per village.
- ≥2 km apart from another village.
Village Level Exclusion Criteria:
- < 80% of HHs suitable for ET installation.
- <70% of HHs willing to have ETs installed.
- Villages being treated by indoor residual spray (IRS) and/or new generation bed net campaigns.
- Participation in previous Screening + ET cRCT.
- <100 and >300 households per village.
- <2 km from another village.
Household Level Inclusion Criteria
- HHs must be suitable for ET installation.
- Provision of consent from heads of HH.
Household Level Exclusion Criteria
- HH not suitable for ET installation (e.g. houses with poor quality thatch roofing or very large eaves or wall gaps, houses in substantial disrepair, unfinished houses under construction, poorly constructed houses, ).
- No provision of consent from heads of HH.
Individual Level Inclusion Criteria
- Children aged ≥ 6 months to < 8 years old at time of enrollment (so all participants are under 10 years old for the duration of clinical follow-up).
- Provision of written, informed consent by parents/care givers.
- Children must reside in villages enrolled in the study and in ETs-treated HHs.
- Hemoglobin at baseline of >7 mg/dL.
Individual Level Exclusion Criteria
- Children aged < 6 months or ≥ 8 years old at time of enrollment.
- No provision of written, informed consent by parents/care givers for child participation.
- Expected to be non-resident during a significant part of the transmission season.
- Hemoglobin at baseline of ≤7 mg/dL, have a known chronic disease, or who have signs of clinical decompensation.
- Participation in another clinical trial investigating a drug, vaccine, medical device or procedure.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: EaveTubes for Control of Vector Borne Diseases in Côte d'Ivoire
The goal of this clinical trial is to test whether In2Care EaveTubes (ETs) as a stand-alone tool can reduce malaria in an area where transmission is driven by insecticide-resistant Anopheles gambiae. Children who live in homes with ETs will be monitored for malaria infection and compared to children living in homes without ETs in Côte d'Ivoire where there is universal coverage of long lasting insecticide nets and pyrethroid resistance is high.
Read the detailed description
In2Care EaveTubes (ETs) are an inexpensive, new vector control product under World Health Organization (WHO) evaluation informed by mosquito ecology to efficiently target malaria vectors. By installing ETs in the walls of the house at eave level that funnel the natural airflow, mosquitoes are drawn in by the same heat and odor cues that typically attract them through the eaves. Once inside an ET, mosquitoes come into contact with insecticide-treated netting placed inside the ET.
The aim of this study is to test whether ETs as stand-alone tool have an effect on the epidemiology of malaria in villages where houses have been modified with the ET intervention. This prospective 2-arm cluster randomized control trial based on a WHO Vector Control Advisory Group approved protocol will include 17 intervention clusters and 17 control clusters. Both arms will have pyrethroid-treated bednets. Based on the population census, 55 households per cluster with eligible children will be randomly selected for recruitment into the active detection cohorts. In the intervention arm, we will enroll eligible children who reside in ET-treated houses. In the control arm, we will enroll children residing in villages without ET-treated houses. The intervention and control cohorts will be followed for 4 months for baseline covariate measurements and 24 months of a clinical follow up period. During case detection visits, blood samples will be taken from all febrile children and tested for malaria infection with rapid diagnostic tests. To assess the impact of the ET on mosquito density, entomological measurements will be conducted monthly in 20 clusters (10 ET, 10 Control) in 10 randomly selected households per cluster. To estimate the infectiousness of malaria vectors, sporozoite rates will be measured in subsets of the collected mosquito samples.
- Conditions
- Malaria
- Being tested
- In2Care EaveTube
- Keywords
- EaveTubes, Housing, Malaria control, LLINs, Cost-effectiveness, Malaria, Vector-borne diseases, Mosquito vectors, Incidence
- Medical subject headings
- Malaria, Vector Borne Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
In2Care EaveTubeDevice
In2Care® EaveTubes (ETs) comprise 15 cm diameter, 20 cm long ventilation tubes with removable netting inserts that are placed in the wall under the roof of houses where they attract malaria mosquitoes at night, block them from entering the house, and contaminate them with a lethal dose of insecticide. In2Care® ET netting inserts have an electrostatically charged coating treated with bio-actives in powder form, which kills insecticide-resistant mosquitoes through high active ingredient dose transfer.
| Study group | Role | What they receive |
|---|---|---|
| In2Care EaveTube | Experimental | EaveTube installation with deltamethrin treated netting; in addition to standard of care (standard pyrethroid-only bednets) Receives: Device: In2Care EaveTube |
| Control | No intervention | Standard of care (standard pyrethroid-only bednets) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence rate of malaria infection
Measured by active infection and clinical malaria case detection in cohorts of 55 children (between 6 months and 10 years old) per cluster, 17 clusters per arm on a biweekly basis in peak transmission season and monthly basis in low transmission season.
Measured: 24 months
Secondary outcomes (6)
Clinical malaria incidence
Measured in children between 6 months to 10 years old living in the study cohorts using passive case detection via the existing community health workers and health centers.
Measured: 24 months
Malaria parasitemia
Measured in children between 6 months to 10 years old in the cohorts of 55 children.
Measured: 24 months
Prevalence of moderate (defined as 7 - 9.9 g/dL hemoglobin) to severe anemia (<7 g/dL hemoglobin)
Measured in children under 5 years of age in the cohorts of 55 children four times: at the start and end of the rainy season (April and November respectively) of Year 1 and Year 2.
Measured: 24 months
Mean numbers of female malaria mosquitoes (An. gambiae s.l., An funestus s.l.) captured in study houses
Measured by CDC light traps in 20 clusters, 10 houses per cluster on a monthly basis.
Measured: 24 months
Malaria parasite sporozoite rate
Assessed in 10% of all anophelines captured by CDC light trap.
Measured: 24 months
Entomological Inoculation Rates
Measured in each study arm as the product of the anopheline vector density and sporozoite rate.
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Feb 2023
- Study start23 Mar 2023
- Primary completionDec 2025 (estimated)
- Study completionDec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (26)Papers the sponsor has linked to this study.
- Other trials for MalariaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 1,870 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Notre Dame
- Sponsor type
- University, hospital or other
- Collaborators
- Institut Pierre Richet, In2Care
- Responsible party
- Principal investigator, John Grieco, University of Notre Dame
- Investigators
- John P Grieco, PhD, Principal investigator, University of Notre Dame
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05736679
- Sponsor's protocol ID
- 22-10-7454
- Status last verified
- May 2025
- First submitted
- 10 Feb 2023
- Last updated
- 23 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Andriessen R, Snetselaar J, Suer RA, Osinga AJ, Deschietere J, Lyimo IN, Mnyone LL, Brooke BD, Ranson H, Knols BG, Farenhorst M. Electrostatic coating enhances bioavailability of insecticides and breaks pyrethroid resistance in mosquitoes. Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):12081-6. doi: 10.1073/pnas.1510801112. Epub 2015 Aug 31.
PubMed 26324912Barreaux AMG, Brou N, Koffi AA, N'Guessan R, Oumbouke WA, Tia IZ, Thomas MB. Semi-field studies to better understand the impact of eave tubes on mosquito mortality and behaviour. Malar J. 2018 Aug 22;17(1):306. doi: 10.1186/s12936-018-2457-4.
PubMed 30134907Barreaux AMG, Oumbouke WA, Tia IZ, Brou N, Koffi AA, N'guessan R, Thomas MB. Semi-field evaluation of the cumulative effects of a "Lethal House Lure" on malaria mosquito mortality. Malar J. 2019 Aug 30;18(1):298. doi: 10.1186/s12936-019-2936-2.
PubMed 31470873Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle K, Moyes CL, Henry A, Eckhoff PA, Wenger EA, Briet O, Penny MA, Smith TA, Bennett A, Yukich J, Eisele TP, Griffin JT, Fergus CA, Lynch M, Lindgren F, Cohen JM, Murray CLJ, Smith DL, Hay SI, Cibulskis RE, Gething PW. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015 Oct 8;526(7572):207-211. doi: 10.1038/nature15535. Epub 2015 Sep 16.
PubMed 26375008Bradley J, Rehman AM, Schwabe C, Vargas D, Monti F, Ela C, Riloha M, Kleinschmidt I. Reduced prevalence of malaria infection in children living in houses with window screening or closed eaves on Bioko Island, equatorial Guinea. PLoS One. 2013 Nov 13;8(11):e80626. doi: 10.1371/journal.pone.0080626. eCollection 2013.
PubMed 24236191Carey JR, Muller HG, Wang JL, Papadopoulos NT, Diamantidis A, Koulousis NA. Graphical and demographic synopsis of the captive cohort method for estimating population age structure in the wild. Exp Gerontol. 2012 Oct;47(10):787-91. doi: 10.1016/j.exger.2012.06.012. Epub 2012 Jul 7.
PubMed 22776134Hayes RJ, Bennett S. Simple sample size calculation for cluster-randomized trials. Int J Epidemiol. 1999 Apr;28(2):319-26. doi: 10.1093/ije/28.2.319.
PubMed 10342698Kirby MJ, Ameh D, Bottomley C, Green C, Jawara M, Milligan PJ, Snell PC, Conway DJ, Lindsay SW. Effect of two different house screening interventions on exposure to malaria vectors and on anaemia in children in The Gambia: a randomised controlled trial. Lancet. 2009 Sep 19;374(9694):998-1009. doi: 10.1016/S0140-6736(09)60871-0. Epub 2009 Sep 3.
PubMed 19732949Koffi AA, Ahoua Alou LP, Adja MA, Chandre F, Pennetier C. Insecticide resistance status of Anopheles gambiae s.s population from M'Be: a WHOPES-labelled experimental hut station, 10 years after the political crisis in Cote d'Ivoire. Malar J. 2013 May 4;12:151. doi: 10.1186/1475-2875-12-151.
PubMed 23641777Koffi AA, Ahoua Alou LP, Kabran JP, N'Guessan R, Pennetier C. Re-visiting insecticide resistance status in Anopheles gambiae from Cote d'Ivoire: a nation-wide informative survey. PLoS One. 2013 Dec 16;8(12):e82387. doi: 10.1371/journal.pone.0082387. eCollection 2013.
PubMed 24358177Krajacich BJ, Slade JR, Mulligan RF, LaBrecque B, Alout H, Grubaugh ND, Meyers JI, Fakoli LS 3rd, Bolay FK, Brackney DE, Burton TA, Seaman JA, Diclaro JW 2nd, Dabire RK, Foy BD. Sampling host-seeking anthropophilic mosquito vectors in west Africa: comparisons of an active human-baited tent-trap against gold standard methods. Am J Trop Med Hyg. 2015 Feb;92(2):415-21. doi: 10.4269/ajtmh.14-0303. Epub 2014 Nov 24.
PubMed 25422393Lengeler C. Insecticide-treated bednets and curtains for preventing malaria. Cochrane Database Syst Rev. 2000;(2):CD000363. doi: 10.1002/14651858.CD000363.
PubMed 10796535Lindsay SW, Snow RW. The trouble with eaves; house entry by vectors of malaria. Trans R Soc Trop Med Hyg. 1988;82(4):645-6. doi: 10.1016/0035-9203(88)90546-9. No abstract available.
PubMed 3256125Lwetoijera DW, Kiware SS, Mageni ZD, Dongus S, Harris C, Devine GJ, Majambere S. A need for better housing to further reduce indoor malaria transmission in areas with high bed net coverage. Parasit Vectors. 2013 Mar 7;6:57. doi: 10.1186/1756-3305-6-57.
PubMed 23497471Oumbouke WA, Tia IZ, Barreaux AMG, Koffi AA, Sternberg ED, Thomas MB, N'Guessan R. Screening and field performance of powder-formulated insecticides on eave tube inserts against pyrethroid resistant Anopheles gambiae s.l.: an investigation into 'actives' prior to a randomized controlled trial in Cote d'Ivoire. Malar J. 2018 Oct 22;17(1):374. doi: 10.1186/s12936-018-2517-9.
PubMed 30348154
Study at a glance
From the registry record, last updated by the sponsor on 23 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- EaveTubes for Control of Vector Borne Diseases in Côte d'Ivoire
- ClinicalTrials.gov ID
- NCT05736679
- Acronym / sponsor ID
- 22-10-7454
- Conditions
- Malaria
- Keywords
- EaveTubes, Housing, Malaria control, LLINs, Cost-effectiveness, Malaria, Vector-borne diseases, Mosquito vectors
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,870 participants (estimated)
- Lead sponsor
- University of Notre DameUniversity, hospital or other
- Collaborators
- Institut Pierre Richet, In2Care
- Study start
- 23 Mar 2023 (actual)
- Primary completion
- Dec 2025 (estimated)
- Study completion
- Dec 2025 (estimated)
- First posted
- 21 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to test whether In2Care EaveTubes (ETs) as a stand-alone tool can reduce malaria in an area where transmission is driven by insecticide-resistant Anopheles gambiae. Children who live in homes with ETs will be monitored for malaria infection and compared to children living in homes without ETs in Côte d'Ivoire where there is universal coverage of long lasting insecticide nets and pyrethroid resistance is high.
Detailed description
In2Care EaveTubes (ETs) are an inexpensive, new vector control product under World Health Organization (WHO) evaluation informed by mosquito ecology to efficiently target malaria vectors. By installing ETs in the walls of the house at eave level that funnel the natural airflow, mosquitoes are drawn in by the same heat and odor cues that typically attract them through the eaves. Once inside an ET, mosquitoes come into contact with insecticide-treated netting placed inside the ET.
The aim of this study is to test whether ETs as stand-alone tool have an effect on the epidemiology of malaria in villages where houses have been modified with the ET intervention. This prospective 2-arm cluster randomized control trial based on a WHO Vector Control Advisory Group approved protocol will include 17 intervention clusters and 17 control clusters. Both arms will have pyrethroid-treated bednets. Based on the population census, 55 households per cluster with eligible children will be randomly selected for recruitment into the active detection cohorts. In the intervention arm, we will enroll eligible children who reside in ET-treated houses. In the control arm, we will enroll children residing in villages without ET-treated houses. The intervention and control cohorts will be followed for 4 months for baseline covariate measurements and 24 months of a clinical follow up period. During case detection visits, blood samples will be taken from all febrile children and tested for malaria infection with rapid diagnostic tests. To assess the impact of the ET on mosquito density, entomological measurements will be conducted monthly in 20 clusters (10 ET, 10 Control) in 10 randomly selected households per cluster. To estimate the infectiousness of malaria vectors, sporozoite rates will be measured in subsets of the collected mosquito samples.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| In2Care EaveTube | Experimental | Device: In2Care EaveTubeEaveTube installation with deltamethrin treated netting; in addition to standard of care (standard pyrethroid-only bednets) |
| Control | No intervention | –Standard of care (standard pyrethroid-only bednets) |
Who may qualify
- Ages
- 6 months to 10 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| In2Care EaveTubeIn2Care® EaveTubes (ETs) comprise 15 cm diameter, 20 cm long ventilation tubes with removable netting inserts that are placed in the wall under the roof of houses where they attract malaria mosquitoes at night, block them from entering the house, and contaminate them with a lethal dose of insecticide. In2Care® ET netting inserts have an electrostatically charged coating treated with bio-actives in powder form, which kills insecticide-resistant mosquitoes through high active ingredient dose transfer. | Device | In2Care EaveTube |
Primary outcome
Incidence rate of malaria infection
Time frame: 24 months
Measured by active infection and clinical malaria case detection in cohorts of 55 children (between 6 months and 10 years old) per cluster, 17 clusters per arm on a biweekly basis in peak transmission season and monthly basis in low transmission season.
6 secondary outcomes
Clinical malaria incidence
Time frame: 24 months
Malaria parasitemia
Time frame: 24 months
Prevalence of moderate (defined as 7 - 9.9 g/dL hemoglobin) to severe anemia (<7 g/dL hemoglobin)
Time frame: 24 months
Mean numbers of female malaria mosquitoes (An. gambiae s.l., An funestus s.l.) captured in study houses
Time frame: 24 months
Malaria parasite sporozoite rate
Time frame: 24 months
Entomological Inoculation Rates
Time frame: 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 May 2025.
- Background: PubMed 26324912Andriessen R, Snetselaar J, Suer RA, Osinga AJ, Deschietere J, Lyimo IN, Mnyone LL, Brooke BD, Ranson H, Knols BG, Farenhorst M. Electrostatic coating enhances bioavailability of insecticides and breaks pyrethroid resistance in mosquitoes. Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):12081-6. doi: 10.1073/pnas.1510801112. Epub 2015 Aug 31.
- Background: PubMed 30134907Barreaux AMG, Brou N, Koffi AA, N'Guessan R, Oumbouke WA, Tia IZ, Thomas MB. Semi-field studies to better understand the impact of eave tubes on mosquito mortality and behaviour. Malar J. 2018 Aug 22;17(1):306. doi: 10.1186/s12936-018-2457-4.
- Background: PubMed 31470873Barreaux AMG, Oumbouke WA, Tia IZ, Brou N, Koffi AA, N'guessan R, Thomas MB. Semi-field evaluation of the cumulative effects of a "Lethal House Lure" on malaria mosquito mortality. Malar J. 2019 Aug 30;18(1):298. doi: 10.1186/s12936-019-2936-2.
- Background: PubMed 26375008Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle K, Moyes CL, Henry A, Eckhoff PA, Wenger EA, Briet O, Penny MA, Smith TA, Bennett A, Yukich J, Eisele TP, Griffin JT, Fergus CA, Lynch M, Lindgren F, Cohen JM, Murray CLJ, Smith DL, Hay SI, Cibulskis RE, Gething PW. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015 Oct 8;526(7572):207-211. doi: 10.1038/nature15535. Epub 2015 Sep 16.
- Background: PubMed 24236191Bradley J, Rehman AM, Schwabe C, Vargas D, Monti F, Ela C, Riloha M, Kleinschmidt I. Reduced prevalence of malaria infection in children living in houses with window screening or closed eaves on Bioko Island, equatorial Guinea. PLoS One. 2013 Nov 13;8(11):e80626. doi: 10.1371/journal.pone.0080626. eCollection 2013.
- Background: PubMed 22776134Carey JR, Muller HG, Wang JL, Papadopoulos NT, Diamantidis A, Koulousis NA. Graphical and demographic synopsis of the captive cohort method for estimating population age structure in the wild. Exp Gerontol. 2012 Oct;47(10):787-91. doi: 10.1016/j.exger.2012.06.012. Epub 2012 Jul 7.
- Background: PubMed 10342698Hayes RJ, Bennett S. Simple sample size calculation for cluster-randomized trials. Int J Epidemiol. 1999 Apr;28(2):319-26. doi: 10.1093/ije/28.2.319.
- Background: PubMed 19732949Kirby MJ, Ameh D, Bottomley C, Green C, Jawara M, Milligan PJ, Snell PC, Conway DJ, Lindsay SW. Effect of two different house screening interventions on exposure to malaria vectors and on anaemia in children in The Gambia: a randomised controlled trial. Lancet. 2009 Sep 19;374(9694):998-1009. doi: 10.1016/S0140-6736(09)60871-0. Epub 2009 Sep 3.
- Background: PubMed 23641777Koffi AA, Ahoua Alou LP, Adja MA, Chandre F, Pennetier C. Insecticide resistance status of Anopheles gambiae s.s population from M'Be: a WHOPES-labelled experimental hut station, 10 years after the political crisis in Cote d'Ivoire. Malar J. 2013 May 4;12:151. doi: 10.1186/1475-2875-12-151.
- Background: PubMed 24358177Koffi AA, Ahoua Alou LP, Kabran JP, N'Guessan R, Pennetier C. Re-visiting insecticide resistance status in Anopheles gambiae from Cote d'Ivoire: a nation-wide informative survey. PLoS One. 2013 Dec 16;8(12):e82387. doi: 10.1371/journal.pone.0082387. eCollection 2013.
- Background: PubMed 25422393Krajacich BJ, Slade JR, Mulligan RF, LaBrecque B, Alout H, Grubaugh ND, Meyers JI, Fakoli LS 3rd, Bolay FK, Brackney DE, Burton TA, Seaman JA, Diclaro JW 2nd, Dabire RK, Foy BD. Sampling host-seeking anthropophilic mosquito vectors in west Africa: comparisons of an active human-baited tent-trap against gold standard methods. Am J Trop Med Hyg. 2015 Feb;92(2):415-21. doi: 10.4269/ajtmh.14-0303. Epub 2014 Nov 24.
- Background: PubMed 10796535Lengeler C. Insecticide-treated bednets and curtains for preventing malaria. Cochrane Database Syst Rev. 2000;(2):CD000363. doi: 10.1002/14651858.CD000363.
- World Health Organization - Global plan for insecticide resistance management in malaria vectors.Link provided by the sponsor.
- World Health Organization, 2019 - Eleventh meeting of the WHO Vector Control Advisory GroupLink provided by the sponsor.
- Anderson L., Simpson D., Stephens M. (2014) Effective Malaria Control Through Durable Housing Improvements: Can we learn new strategies from past experience? Habitat Humanity International Global Programs DepartmentLink provided by the sponsor.
- Uganda Housing Modification Study (UHMS)Link provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Malaria
Not yet recruiting
Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection
Healthy Volunteer, Malaria
RecruitingObservational study
Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
Malaria
RecruitingPhase 1
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
Malaria
RecruitingPhase 1/2
DON in Pediatric Cerebral Malaria
Malaria, Cerebral
Not yet recruitingPhase 1
Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years
Malaria Vaccine
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John P Grieco, PhD principal investigator
University of Notre Dame
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing In2Care EaveTube in people with Malaria, run by University of Notre Dame at 1 site in Côte d’Ivoire.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 23 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Côte d’Ivoire. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence rate of malaria infection (time frame: 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05736679, which also lists 26 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 May 2025.